scholarly journals OP13.04: Predicting moderate to severe fetal anemia after previous intrauterine transfusion

2015 ◽  
Vol 46 ◽  
pp. 91-91
Author(s):  
P. Acharya
Keyword(s):  
Fetal Anemia ◽  
Intrauterine Transfusion

scholarly journals Intrauterine Transfusion Complicated by Umbilical Artery Thrombosis

2019 ◽  
Vol 2019 ◽  
pp. 1-4
Author(s):  
Roopali V. Donepudi ◽  
Kenneth J. Moise
Keyword(s):  
Preterm Delivery ◽  
Umbilical Artery ◽  
Fetal Death ◽  
Male Infant ◽  
Full Term ◽  
Fetal Anemia ◽  
Optimal Management ◽  
Artery Thrombosis ◽  
Intrauterine Transfusion

Background. Fetal anemia results from several conditions; however intrauterine transfusion (IUT) remains the treatment for severe cases. The complications of this procedure are rare and yet can result in preterm delivery or fetal death. Case. 31 y/o G3P2002 with Rh alloimmunization underwent IUT from 19 to 35 weeks. Umbilical artery thrombosis was noted after her 5th IUT. Further transfusions were performed without any complications and she delivered a full term male infant with APGARS of 8 and 9 at 1 and 5 minutes, respectively. Conclusion. The complication of umbilical artery thrombosis is unusual and the optimal management is unclear. We report such a case and propose that the presence of Hyrtl’s anastomosis near the placental cord insertion may explain the reassuring fetal status throughout the pregnancy.

scholarly journals Sonographic Demonstration of Intracranial Hemorrhage in a Fetus with Hydrops Fetalis due to Rh Alloimmunization after Intrauterine Intravascular Transfusion: A Case Report and Review of the Literature

2018 ◽  
Vol 2018 ◽  
pp. 1-5
Author(s):  
Rauf Melekoglu ◽  
Ebru Celik ◽  
Hasim Kural
Keyword(s):  
Case Report ◽  
Intracranial Hemorrhage ◽  
Intraventricular Hemorrhage ◽  
Case Reports ◽  
Rare Complication ◽  
Fetal Anemia ◽  
Red Cell ◽  
Review Of The Literature ◽  
Intrauterine Transfusion ◽  
Sonographic Demonstration

Intrauterine transfusion is the most common and successful intrauterine procedure for the treatment of fetal anemia due to red cell alloimmunization. Fetal intracranial hemorrhage is a very rare complication of intrauterine transfusion in patients with Rh(D) alloimmunization and it has been demonstrated only in a few case reports in the literature. Herein, we described a case of grade IV intraventricular hemorrhage that was diagnosed following the first intrauterine transfusion and reviewed the literature about the fetal intracranial hemorrhage that occurred after intrauterine intravascular transfusion procedure.

The reversal of hydrops fetalis by intravascular intrauterine transfusion in severe isoimmune fetal anemia

1988 ◽  
Vol 158 (4) ◽  
pp. 914-919 ◽  
Author(s):  
Peter A.T. Grannum ◽  
Joshua A. Copel ◽  
Fernando R. Moya ◽  
Angela L. Scioscia ◽  
Jorge Andres Robert ◽  
...  
Keyword(s):  
Hydrops Fetalis ◽  
Fetal Anemia ◽  
Intrauterine Transfusion

Neonatal outcome after fetal anemia managed by intrauterine transfusion

2015 ◽  
Vol 174 (11) ◽  
pp. 1535-1539 ◽  
Author(s):  
C. Garabedian ◽  
T. Rakza ◽  
D. Thomas ◽  
B. Wibaut ◽  
P. Vaast ◽  
...  
Keyword(s):  
Neonatal Outcome ◽  
Fetal Anemia ◽  
Intrauterine Transfusion

scholarly journals Hemolytic disease of the fetus and newborn: managing the mother, fetus, and newborn

Hematology ◽  
2015 ◽  
Vol 2015 (1) ◽  
pp. 146-151 ◽  
Author(s):  
Meghan Delaney ◽  
Dana C. Matthews
Keyword(s):  
Heart Failure ◽  
Pregnant Women ◽  
Blood Group ◽  
Acute Phase ◽  
Maternal Blood ◽  
Fetal Anemia ◽  
Red Cell ◽  
Hemolytic Disease ◽  
Cell Destruction ◽  
Intrauterine Transfusion

AbstractHemolytic disease of the fetus and newborn (HDFN) affects 3/100 000 to 80/100 000 patients per year. It is due to maternal blood group antibodies that cause fetal red cell destruction and in some cases, marrow suppression. This process leads to fetal anemia, and in severe cases can progress to edema, ascites, heart failure, and death. Infants affected with HDFN can have hyperbilirubinemia in the acute phase and hyporegenerative anemia for weeks to months after birth. The diagnosis and management of pregnant women with HDFN is based on laboratory and radiographic monitoring. Fetuses with marked anemia may require intervention with intrauterine transfusion. HDFN due to RhD can be prevented by RhIg administration. Prevention for other causal blood group specificities is less studied.

scholarly journals P20.01: Fetal anemia after stillbirth of a twin in a TTTS: a case of emergency intrauterine transfusion

2014 ◽  
Vol 44 (S1) ◽  
pp. 304-304
Author(s):  
B. Walker Labarca ◽  
J. Astudillo ◽  
A. Insunza ◽  
M. Yamamoto
Keyword(s):  
Fetal Anemia ◽  
Intrauterine Transfusion

Middle Cerebral Artery Doppler Changes following Fetal Transfusion Performed with and without Fetal Anesthesia

2017 ◽  
Vol 35 (07) ◽  
pp. 682-687 ◽  
Author(s):  
Kristen Uquillas ◽  
Myrna Aboudiab ◽  
Lisa Korst ◽  
Arlyn Llanes ◽  
Brendan Grubbs ◽  
...  
Keyword(s):  
Middle Cerebral Artery ◽  
Umbilical Cord ◽  
Cerebral Artery ◽  
Gestational Age ◽  
Peak Systolic Velocity ◽  
Fetal Anemia ◽  
Intravenous Anesthesia ◽  
Intrauterine Transfusion ◽  
The Difference ◽  
The Relationship

Objective The objective of this study was to test the association between fetal intravenous anesthesia and the change in middle cerebral artery peak systolic velocity (MCA-PSV) in patients undergoing intrauterine transfusion (IUT) for suspected fetal anemia. Study Design We retrospectively examined data from all patients who underwent IUT via umbilical cord route from 2007 to 2016. We calculated the change of the MCA-PSV multiple of median (MoM) as the difference in MCA-PSV MoM between the pre- and immediate postoperative measurements for the first IUT. The change in MCA-PSV MoM was compared between those who did and did not receive fetal anesthesia using Kruskal–Wallis' testing. Results Of 62 patients, 37 (59.7%) received intravenous fetal anesthesia and 25 (40.3%) did not. The change in MCA-PSV MoM did not differ between those who did and did not receive fetal anesthesia (median: 0.57 [interquartile range, IQR: +0.42 to +0.76] vs. median 0.57 [IQR: +0.40 to +0.81], p = 1.000). The relationship remained insignificant when stratifying by gestational age, length of procedure, initial MCA-PSV, and when excluding hydropic fetuses. Conclusion Among women undergoing IUT, there was no evidence that the use of fetal anesthesia was associated with a change in the pre- versus postoperative change in MCA-PSV MoM.

Fetal Intrauterine Transfusion

2017 ◽  
Vol 1 (1) ◽  
pp. 27-29
Author(s):  
Amitha Indersen
Keyword(s):  
Treatment Strategy ◽  
Peak Systolic Velocity ◽  
Noninvasive Monitoring ◽  
Comprehensive Treatment ◽  
Blood Transfusions ◽  
Fetal Anemia ◽  
Fetal Blood ◽  
Monitoring And Diagnosis ◽  
Intrauterine Transfusion ◽  
Treatable Condition

ABSTRACT Fetal anemia is a recognizable and treatable condition. It requires identification of the etiology to plan a comprehensive treatment strategy. Fetal blood transfusions help tide over crisis and avert fetal cardiovascular decompensation or deterioration due to the anemia. Based on the cause and the fetal condition, the timing and requirement for transfusion are determined. At present, noninvasive monitoring with fetal middle cerebral arterial Doppler peak systolic velocity is the standard for monitoring and diagnosis of fetal anemia. How to cite this article Indersen A. Fetal Intrauterine Transfusion. World J Anemia 2017;1(1):27-29.

Parvovirus

2018 ◽  
Author(s):  
Amol Purandare ◽  
Barbara A. Jantausch
Keyword(s):  
Parvovirus B19 ◽  
Antiviral Agents ◽  
Neurodevelopmental Outcome ◽  
Congenital Infection ◽  
Future Research ◽  
Fetal Anemia ◽  
Intrauterine Transfusion ◽  
History Of ◽  
Parvovirus B19 Infection ◽  
Neurodevelopmental Impairment

Parvovirus B19 is a common infection in humans that occurs worldwide. Parvovirus B19 is transmitted through exposure to respiratory droplets, blood, and blood products, and through mother-to-child transmission (MTCT) in utero. Intrauterine parvovirus B19 infection is a rare occurrence during pregnancy but can result in significant morbidity and mortality for the fetus, including severe fetal anemia and nonimmune fetal hydrops (NIFH). Intrauterine transfusion can be successful in treating fetal anemia. Neurodevelopmental impairment has been reported in infants with congenital infection who have received intrauterine transfusion (IUT). Future research on the development of antiviral agents for the treatment of parvovirus B19 infection in pregnant women is needed, along with the development of a parvovirus B19 vaccine. Longitudinal studies to evaluate neurodevelopmental outcome of infants with a history of congenital parvovirus B19 infection are needed in order to facilitate the optimal evaluation and management of these infants.

scholarly journals Plasmapheresis for the Treatment of Anti-M Alloimmunization in Pregnancy

2020 ◽  
Vol 2020 ◽  
pp. 1-4
Author(s):  
Yohei Maki ◽  
Junko Ushijima ◽  
Seishi Furukawa ◽  
Hiroko Inagaki ◽  
Hiroyuki Takenouchi ◽  
...  
Keyword(s):  
Fetal Death ◽  
Intrauterine Fetal Death ◽  
Fetal Anemia ◽  
Severe Anemia ◽  
Hemolytic Disease ◽  
Intrauterine Transfusion ◽  
History Of ◽  
Intrauterine Blood Transfusion ◽  
Antenatal Treatment ◽  
In Pregnancy

Intrauterine transfusion is the standard antenatal treatment for a fetus with severe anemia. Plasmapheresis is an alternative treatment for cases with a history of severe hemolytic disease of the fetus and newborns at less than 20 weeks of gestation. There is only one previous report of plasmapheresis for the anti-M alloimmunization in pregnancy, and we report here on the successful treatment of plasmapheresis for anti-M alloimmunization. A woman with a history of intrauterine fetal death at 24 weeks of gestation due to severe fetal anemia caused by anti-M alloimmunization received plasmapheresis once or twice a week from 14 weeks of gestation onward. An intrauterine blood transfusion was conducted at 28 weeks, and a cesarean section was performed at 31 weeks. The infant had anemia and jaundice but was discharged at day 46. Plasmapheresis may delay the development of fetal anemia and reduce the risk of early and repeat intrauterine transfusion in cases of anti-M alloimmunization in pregnancy.

Sign in / Sign up

Export Citation Format

Share Document